An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Фаза 3 – широко изпитване преди одобрение
Заболявания:
B-cell malignancies
Спонсор: BeOne Medicines AG
Налично на:
БГ
Обобщение
Trial status: Authorised
Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival
The primary endpoint of the study is safety as assessed by incidence of all TEAEs and SAEs.
Описание
Progression-free Survival per investigator assessment, Duration of Response per investigator assessment, Overall Survival
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 343 participants
БГ
EN